4.4 Review

COVID-19 and autoimmune diseases

期刊

CURRENT OPINION IN RHEUMATOLOGY
卷 33, 期 2, 页码 155-162

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0000000000000776

关键词

autoimmune diseases; COVID-19; cross-reactivity; molecular mimicry; SARS-CoV-2

资金

  1. National Natural Science Foundation for Young Scientists of China [81502732]
  2. National Institutes of Health (NIH) [R01AI097134, R01AR070148]
  3. Lupus Research Alliance
  4. urgent grant of Hunan Province for fighting against coronavirus disease-2019 epidemic [2020SK3005]

向作者/读者索取更多资源

This study evaluates the association between SARS-CoV-2 infection and autoimmunity, highlighting similarities between COVID-19 and autoimmune diseases in immune responses and potential development of autoimmune conditions. Patients with COVID-19 may develop autoimmune diseases post-infection, emphasizing the importance of medication adherence in preventing disease flares.
Purpose of review The aim of this study was to evaluate the relationship between infection with SARS-CoV-2 and autoimmunity. Recent findings Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome (SARS) associated coronavirus 2 (SARS-CoV-2). Although most of the infected individuals are asymptomatic, a proportion of patients with COVID-19 develop severe disease with multiple organ injuries. Evidence suggests that some medications used to treat autoimmune rheumatologic diseases might have therapeutic effect in patients with severe COVID-19 infections, drawing attention to the relationship between COVID-19 and autoimmune diseases. COVID-19 shares similarities with autoimmune diseases in clinical manifestations, immune responses and pathogenic mechanisms. Robust immune reactions participate in the pathogenesis of both disease conditions. Autoantibodies as a hallmark of autoimmune diseases can also be detected in COVID-19 patients. Moreover, some patients have been reported to develop autoimmune diseases, such as Guillain--Barre syndrome or systemic lupus erythematosus, after COVID-19 infection. It is speculated that SARS-CoV-2 can disturb self-tolerance and trigger autoimmune responses through cross-reactivity with host cells. The infection risk and prognosis of COVID-19 in patients with autoimmune diseases remains controversial, but patient adherence to medication regimens to prevent autoimmune disease flares is strongly recommended. We present a review of the association between COVID-19 and autoimmune diseases, focusing on similarities in immune responses, cross-reactivity of SARS-CoV-2, the development of autoimmune diseases in COVID-19 patients and the risk of COVID-19 infection in patients with preexisting autoimmune conditions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据